Merck KGaA Research Grants for Drug Discovery 2022 now open

Merck KGaA, headquartered in Germany, has announced their 2022 Research Grants.  They invite proposals towards the next game-changing biology discoveries including target validation and drug discovery in cancer, autoimmune/neuroinflammatory disease, infertility and anti-aging (senescence).

Click here for more detailed information on their focus areas of interest.

Merck are offering grants of up to €500,000 (approx. AUD 740,000) per year for up to three years with an option of extension.

UniQuest will work with you to frame your innovation for the industry audience and to maintain the potential for a future patent position, with a focus on addressing Merck’s criteria, ie innovativeness, commercial potential, path forward to potential product, probability of success, team strength and strategic fit with Merck.

Therapeutic areas of interest

Cancer

Autoimmune

Neuroinflammatory disease

Infertility

Anti-aging (senescence)

Next steps

  • Download Merck flyer
  • Download the Research Grants application form and discuss with UniQuest
  • Email UniQuest or contact one of the team members listed below to discuss your research and potential non-confidential application
  • Submit application to industryconnect@uniquest.com.au by 24th August 2022. This deadline is for internal review and feedback to researchers by UniQuest.
  • Deadline for submissions to Merck 31st August 2022.

Merck KGaA Research Grants for Drug Discovery 2022 now open

For more information in your research area, contact:


Dr Craig Belcher

c.belcher@uniquest.com.au


Dr Tamsin Terry

t.terry@uniquest.com.au


Dr David Markwell

d.markwell@uniquest.com.au


Dr George Adamson

g.adamson@uniquest.com.au


Julian Vultaggio

j.vultaggio@uniquest.com.au

Contact us

Contact us for more information about this and other Industry Connect events.

Contact us